AzTrials
AzTrials

Acute Kidney InjuryCost-AKINCT07719569

Treatment Costs of Kidney Injury in Patients Having Heart Surgery in the UK

An observational study of Acute Kidney Injury, run by The Royal Wolverhampton Hospitals NHS Trust at 1 site in United Kingdom.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Single-centre retrospective analysis of prospectively collected data with propensity matched scoring groups (AKI v/s non-AKI). Data collection from databases (or their equivalent): PATS Dendrite, Electronic Medical Records, TD-web (results Portal), MedTrack (ICU database), iSite (Radiology), SPY (Long-term status) Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Kidney Injury
How many people
4,600 participants
Where
1 siteUnited Kingdom
Study dates
1 Oct 2026to 1 Apr 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study will include patients undergoing elective or in-hospital urgent cardiac surgery requiring cardiopulmonary bypass at the participating cardiac surgery centre.

Who may be able to join

  • Underwent elective or in-house urgent cardiac surgery at the Royal Wolverhampton NHS Trust between 1st January 2013 and 31st December 2025, excluding those who had surgery during 2020 and 2021 due to the confounding effect of COVID-19 on acute kidney injury incidence.
  • Cardiopulmonary bypass (CPB) was utilised during the cardiac surgical procedure.
  • A complete minimum dataset is available within the study databases, comprising: age, sex, history of diabetes, left ventricular ejection fraction (LVEF), surgical priority, pre-operative haemoglobin and serum creatinine (SCr) levels, type of cardiac surgery performed, CPB duration, EuroSCORE or logistic EuroSCORE, renal replacement therapy (RRT) use, and post-operative day 1 and/or day 2 and/or day 3 SCr values.

Who cannot join

  • The procedure was performed as an emergency surgery.
  • Required data fields are incomplete or unavailable.
  • Surgery was performed off-pump, without the use of cardiopulmonary bypass.
  • The patient was dialysis-dependent prior to surgery.
  • The patient had a pre-operative estimated glomerular filtration rate (eGFR) of less than 20 mL/min/1.73 m².
  • The cardiac procedure required deep hypothermic circulatory arrest (DHCA).
  • The patient has exercised their right to opt out of research data use.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site
  • The Royal Wolverhampton NHS Trust

    Wolverhampton, West Midlands, WV10 0QP

Other trials in United Kingdom

About this study

Official title: Treatment Costs of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK: A Retrospective Study

Single-centre retrospective analysis of prospectively collected data with propensity matched scoring groups (AKI v/s non-AKI). Data collection from databases (or their equivalent): PATS Dendrite, Electronic Medical Records, TD-web (results Portal), MedTrack (ICU database), iSite (Radiology), SPY (Long-term status)

Read the detailed description

BACKGROUND Cardiac surgery associated acute kidney injury (CSA-AKI) is reported in 25-40% of patients. This variability is due to a spectrum of definitions used to classify AKI. AKI definition and staging are based on the Risk, Injury, Failure, Loss, End-stage kidney disease (RIFLE) criteria and the Acute Kidney Injury Network (AKIN) criteria, which have been further refined in the Kidney Disease: Improving Global Outcomes (KDIGO) AKI working group guidelines. It is now customary to use the KDIGO definition or its modified version - the AKIN consensus criteria.

The development of AKI in the post-op cardiac surgery setting is associated with significant morbidity, mortality, prolonged intensive care (ICU) \& in-hospital stays, increased treatment costs and poorer long-term survival and quality of life. Despite the ability to identify patients at high risk preoperatively, no effective strategy has yet been established to prevent CSA-AKI.

RATIONALE FOR CURRENT STUDY Acute kidney injury (AKI) is associated with substantial increases in healthcare costs among patients undergoing cardiac surgery. One study estimated that AKI increases costs by $19,212 (£14,437) per patient (non-UK data). In a more recent US study published in 2018, the additional cost attributable to postoperative AKI was estimated at $38,358 (£28,824). This was accompanied by a nearly 10-fold increase in mortality (13.9% vs 1.3%) and a doubling of the mean in-hospital length of stay (18.2 vs 8.6 days) compared with patients without AKI. Similarly, ICU length of stay is significantly prolonged in patients who develop AKI after coronary artery bypass grafting (CABG), with a mean of 5.5 days versus 2.2 days in those without AKI.

STUDY OBJECTIVES Primary Objective: To compare the costs of treatment for patients who develop different stages of cardiac surgery-associated acute kidney injury (CSA-AKI), with the costs for patients who do not develop CSA-AKI, in a UK cardiac surgery population.

Secondary objectives: To determine the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI) using the modified KDIGO criteria (overall and stratified by stage). To compare ICU and in-hospital length of stay. To evaluate the costs of ICU treatment and overall in-hospital stay. To assess survival rates during the index admission and at the time of study follow-up. To calculate the overall hospital costs for the cardiac surgery episode.

STUDY DESIGN This is a single centre, propensity-matched, retrospective study involving patients who developed AKI after cardiac surgery (CSA-AKI) compared to propensity-matched (1:1) non-AKI patients. It involves retrieving patients' clinical data which was prospectively recorded during their stay when they underwent cardiac surgery at The Royal Wolverhampton NHS Trust in the UK. The data are currently within the PATS Dendrite cardiac surgery database, Electronic Medical Records, TD-web (results Portal), MedTrack (ICU database), iSite (Radiology), SPY (Long-term status) databases, or their equivalents. These are clinical databases used during routine care.

The PATS dendrite database records pre-op, intra-op and post-op data pertaining to patient characteristics, operative details, ICU and ward stay including complications. Data recorded include date of operation, participant's age, body mass index \& gender, risks factors (diabetes, left ventricular function, urgency of procedure), type of procedure, Log Euroscore, cardiopulmonary bypass time, date of extubation, need for inotropes, any complications (respiratory including additional respiratory support, re-exploration, arrhythmias, neurological dysfunction, renal dysfunction, blood transfusion, gastro-intestinal problems), date of ICU discharge, ICU re-admission, date of hospital discharge, participant status at time of discharge and discharge destination. This data is independently verified by the cardiac audit personnel and then the core data is submitted to NICOR from where surgeon-specific and Unit-specific mortality data is confirmed and published on the DoH/SCTS website.

The MedTrack Database records the patients' complications and length of stay on the ICU. The iSite details all the radiological investigations while the TD-Web includes all the investigations results (e.g. blood analysis). Data on all databases are recorded contemporaneously. The Clinical Web Portal (Electronic Medical Records) will be used to cross check this information. Some data may need to be retrieved from the medical records. Survival data will be retrieved from the SPY database while hospital cost data will be requested from the hospital finance department.

This study (data collection) will run over a period of three months. Thereafter, data analysis \& interpretation, manuscript writing \& publication may take up to another three months.

The site research team will extract data from the clinical databases directly into Microsoft Excel spreadsheets. Initial data extraction will involve extracting the pre-propensity matching data for all eligible patients, which will be shared with the statistician for propensity matching. Following propensity matching, further data extraction will take place to collect the post-propensity matching data from the AKI and non-AKI propensity-matched groups. Any missing data will be cross-checked using the Clinical Web Portal or original medical records where necessary.

Being tested
No Intervention: Observational Cohort
Medical subject headings
Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No Intervention: Observational CohortOther

    No intervention

Study groups in NCT07719569
Study groupRoleWhat they receive
Patients who developed AKI in their post-operative phaseConsecutive patients who have undergone cardiac surgery and who developed AKI in their post-operative phase will be selected
Patients who did not develop AKI in their post-operative phaseThe patients who developed AKI group will be propensity-matched 1:1 to patients who did not develop AKI
Receives: Other: No Intervention: Observational Cohort

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall cost of treatment in £ for the each KDIGO stage of CSA-AKI

    Based on the KDIGO clinical practice guidelines, AKI is defined in relation to the change in serum creatinine (SCr), use of RRT (Renal Replacement Therapy) and urine output. For this study, CSA-AKI is defined (modified KDIGO) as when any one of the following three criteria are met:

    1. An increase in serum creatinine (SCr) by ≥0.3 mg/dl (≥26.5 micromol/l) within 72 hours of surgery compared to the baseline value; or
    2. An increase in SCr by ≥1.5 times from SCr value at baseline within 72 hours of surgery; or
    3. Use of RRT within 7 days of surgery.

    Measured: From date each patient had surgery to the date each patient discharged from hospital, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction

Secondary outcomes (6)
  1. Number of patients with CSA-AKI

    Incidence of CSA-AKI overall and by KDIGO stage

    Measured: From date each patient had surgery to date each patient discharged from hospital, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), , assessed at point of data extraction

  2. Days patient spent in ICU

    Duration of patient's ICU stay following surgery (days)

    Measured: From date each patient had surgery to date each patient discharged from ICU, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction

  3. Average cost of ICU stay in £ for each KDIGO CSA-AKI stage

    Costs of ICU stay (HRG) for the KDIGO CSA-AKI stages

    Measured: From date each patient had surgery to date each patient discharged from ICU, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction

  4. Length of time each patient spent in hospital in days

    In-hospital stay duration (days)

    Measured: From date each patient had surgery to date each patient discharged from hospital, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction

  5. Number of patients alive upon discharge from hospital

    In-hospital survival

    Measured: From date each patient had surgery to date each patient discharged from hospital, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction

  6. Number of patients alive at the point of study data collection

    Long term survival at time of study

    Measured: From date each patient had surgery to date of data collection, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion1 Apr 2027 (estimated)
  4. Study completion1 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
4,600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07719569
Sponsor's protocol ID
2026CAR150
Other IDs
354746
Acronym
Cost-AKI
Status last verified
Jul 2026
First submitted
7 Jul 2026
Last updated
22 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury, run by The Royal Wolverhampton Hospitals NHS Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall cost of treatment in £ for the each KDIGO stage of CSA-AKI (time frame: From date each patient had surgery to the date each patient discharged from hospital, for all eligible patients who underwent surgery between 1st January 2013 and 31st December 2025 (varies from patient to patient), assessed at point of data extraction). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in